Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide versus usual care for obesity-related HFpEF
ACTRN12624000270516Phase 4Recruiting
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirzepatide in heart failure with preserved ejection fraction (HFpEF) and obesity (2 arms), sponsored by Baker Heart and Diabetes Institute. Primary endpoint: Primary: pulmonary capillary wedge pressure/work rate ratio adjusted for body weight. Started May 2026; status: recruiting.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on ACTRN12624000270516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000270516.